Zhou G, Miura Y, Shoji H, Yamada S, Matsuishi T
First Department (Neurology) of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):229-31. doi: 10.1136/jnnp.70.2.229.
To evaluate the correlation between changes in platelet monoamine oxidase type B (MAO-B) activity and plasma beta-phenylethylamine (PEA) concentrations in patients with Parkinson's disease and controls.
Platelet MAO-B activity and plasma PEA were measured with gas chromatography-mass spectrometry (GC-MS) in patients with Parkinson's disease treated with levodopa (12 men and 12 women) or selegiline (three men and three women), and physically healthy subjects as a control group (10 men and 10 women).
Platelet MAO-B activity was significantly higher in the Parkinson's disease group (mean 542 (SD 318) pmol/10(7) platelets/30 min) than in the control group (mean 349 (SD 307) pmol/10(7) platelets/30 min) (p<0.05). By contrast, the plasma PEA concentrations in patients with Parkinson's disease were significantly lower than in the control group (mean 532 (SD 243) pg/ml; 931 (SD 560) pg/ml) (p<0.01). The plasma PEA concentrations in patients with Parkinson's disease treated with selegiline were prominently higher than in patients with no selegiline treatment (p<0.001). There was a significantly negative correlation between platelet MAO-B activity and plasma PEA concentrations in patients (n=24, r=-0.466, p<0.001).
The increase in platelet MAO-B activity and decrease in plasma PEA concentrations in patients with Parkinson's disease may be involved in the pathophysiological processes of the disease, and these changes are reversed by treatment with selegiline.
评估帕金森病患者及对照组血小板B型单胺氧化酶（MAO - B）活性变化与血浆β - 苯乙胺（PEA）浓度之间的相关性。
采用气相色谱 - 质谱联用（GC - MS）法测定接受左旋多巴治疗的帕金森病患者（12名男性和12名女性）或司来吉兰治疗的帕金森病患者（3名男性和3名女性）以及身体健康的受试者作为对照组（10名男性和10名女性）的血小板MAO - B活性和血浆PEA水平。
帕金森病组血小板MAO - B活性（平均542（标准差318）pmol/10⁷血小板/30分钟）显著高于对照组（平均349（标准差307）pmol/10⁷血小板/30分钟）（p<0.05）。相比之下，帕金森病患者的血浆PEA浓度显著低于对照组（平均532（标准差243）pg/ml；931（标准差560）pg/ml）（p<0.01）。接受司来吉兰治疗的帕金森病患者的血浆PEA浓度显著高于未接受司来吉兰治疗的患者（p<0.001）。患者血小板MAO - B活性与血浆PEA浓度之间存在显著负相关（n = 24，r = -0.466，p<0.001）。
帕金森病患者血小板MAO - B活性增加和血浆PEA浓度降低可能参与了该疾病的病理生理过程，且这些变化可通过司来吉兰治疗得到逆转。
